Clinical Trial

Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 13, 2023 (before its estimated December 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
This study aims to observe and explore the efficacy and safety of Penpulimab combined with chemotherapy for neoadjuvant and adjuvant therapy in patients with resectable head and neck squamous cell carcinoma.
Trial Details
NCT Number NCT06081673
Lead Sponsor Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Conditions Head and Neck Squamous Cell Carcinoma
Enrollment 72 participants
Start Date 2023-10-30
Primary Completion 2024-12-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2023-10-13